Upadacitinib shows effectiveness in atopic dermatitis patients

A recent study shows that upadacitinib is effective for treating moderate to severe atopic dermatitis (AD). The findings suggest that patients experience improvements as early as one month after starting the treatment and can maintain these benefits for up to a year. In the UP-TAINED study, 351 patients took either 15 mg or 30 mg of upadacitinib daily. The main goal was to see how many patients achieved disease control, measured by specific scoring methods, at three months and sustained that control for two years. Results indicate that 68.8% of patients gained disease control after one month. This improved to 71.0% at three months and stayed at about 70.9% through twelve months. Additionally, over half of the patients reached a low severity score for Eczema after one month, which increased to 73.0% after three months. At twelve months, many patients with hand and facial eczema reported clear or almost clear skin. Overall, the treatment was well tolerated. Though there were some adverse effects reported, most were mild or moderate. The study concluded that upadacitinib showed significant effectiveness in treating AD, particularly in hard-to-treat areas. However, some limitations include the potential overestimation of results due to patients dropping out and the study's focus on a German population, which may affect how universally its findings apply. The research was partly funded by AbbVie, the drug's manufacturer. Some authors of the study have ties to the company, which could influence the findings.